Biogen has taken up an option on a technology developed by Denali that it thinks could help improve the safety and efficacy of amyloid-targeting drugs for Alzheimer’s disease. The technology ...

Denali and partner Biogen BIIB have collaborated to develop and commercialize small molecule inhibitors of LRRK2. Biogen is conducting the global phase IIb LUMA study, which is evaluating the ...

Deutsche Bank (ETR:DBKGn) initiated coverage on Denali Therapeutics Inc. (NASDAQ: NASDAQ:DNLI) with a Buy rating and set a price target of $31.00. The new assessment comes as Denali's shares are seen ...

Biogen proposes to buy remaining stake in Sage in $442 million deal January 10, 2025 Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage ...

Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry’s decline of 14.3%. The stock has also ...